Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 4404Urinary Bladder Neoplasms 1080Carcinoma, Renal Cell 1042Kidney Neoplasms 568Breast Neoplasms 454Neoplasms 406Carcinoma, Transitional Cell 301Neoplasm Metastasis 251Lung Neoplasms 243Testicular Neoplasms 202Melanoma 196Colorectal Neoplasms 194Ovarian Neoplasms 165Carcinoma, Non-Small-Cell Lung 150Non-Muscle Invasive Bladder Neoplasms 136Sarcoma 135Pancreatic Neoplasms 125Colonic Neoplasms 121Head and Neck Neoplasms 117Uterine Cervical Neoplasms 116Wilms Tumor 108Recurrence 106Motor Activity 100Urologic Neoplasms 90Stomach Neoplasms 89Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 81Adenocarcinoma 79

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Metastatic Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00636090 2013-12-04

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Duke University

Completed
35 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡